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Background/aim: Autoimmune diseases are a remarkable issue for researchers due to their adverse effects on the auditory system, but
for primary Sjögren’s syndrome (pSS) there is little research on the comprehensive audiological findings in literature. The main objective
of this study was to investigate the medial olivocochlear efferent functions of subjects with pSS and to examine the audiological findings.
Materials and methods: The study included 36 subjects with pSS and 36 healthy subjects. All the subjects underwent testing including
pure tone, speech, and high frequency audiometry; tympanometry and acoustic reflexes; distortion product otoacoustic emissions
(DPOAE); and suppression of DPOAE.
Results: The hearing thresholds of the pSS group were higher than those of the control at all frequencies (P < 0.001). Minimal to
mild sensorineural hearing loss was observed in 52.77% of all the subjects with pSS. Additionally, all of the subjects had type A curve
tympanograms, but the static compliances of the pSS group were lower and the acoustic reflex thresholds were higher than in the control
(P < 0.001). In suppression levels of DPOAE, no statistically significant difference was found between the groups (P > 0.05).
Conclusion: The study indicates that because of obtaining normal suppression levels in DPOAE, the medial olivocochlear efferent
system is functional in pSS. However, there is a need for more tests, including auditory brainstem response, to evaluate the afferent
auditory system in pSS.
Key words: Sjögren’s syndrome, hearing loss, medial olivocochlear, efferent system

1. Introduction
Primary Sjögren’s syndrome (pSS) is an autoimmune
disorder characterized by eye dryness and salivary
hypofunction due to inflammation of lacrimal and salivary
glands [1]. The incidence of pSS in women is higher than
in men with the highest incidence of disease at about 40–
50 years in women [2–4].
Different anatomical regions of the auditory system
may be affected by pSS, resulting in symptoms such as
otalgia, tinnitus, vertigo, and hearing loss. There is little
research on the pathophysiological impact that pSS may
have on the human auditory system. While there are no
robust findings about the effects of pSS, especially for the
outer ear and middle ear, the possible reasons for auditory
symptoms are thought to be dryness of the ear canal
epidermis, middle and inner ear fluids, and dysfunction
of the Eustachian tube [5,6]. On the other hand, there are
many hypotheses about the pathophysiological impact of

pSS on the inner ear. The inner ear is defined as a sensory
organ that contains perilymph and endolymph fluid and
it transduces sound waves into senses of hearing to be
used by the auditory neural parts. These neurosensory
functions are tightly bound to the regulation of molecules
in the perilymph and endolymph fluid volume in the inner
ear [6]. Change in the volume of the inner ear fluids can
disrupt the molecular structure of the fluids and cause
hearing loss. Additionally, ototoxic drugs used during
the treatment of autoimmune inner ear diseases can
cause the damage of intracellular fluids and change the
molecular concentrations for physiological mechanisms.
Furthermore, autoantibodies are produced in perilymph
and endolymph fluids in normal hearing physiology, but
in diseases such as pSS they are produced inadequately
[5,6]. Some studies showed that the incidence of mild to
severe hearing loss in patients with pSS was predicted
as 78.38%, though many patients were unaware of their
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hearing loss [7]. Other studies asserted that patients with
pSS have higher hearing thresholds than healthy subjects
in the 500–3000 Hz frequency range [8], and recent
studies have concentrated on high-frequency hearing
loss in pSS [8,9]. While the present paper concentrates
on medial olivocochlear system functions in pSS, hearing
loss, including high-frequency hearing loss, is roughly
evaluated as well.
In the diagnosis of hearing loss and medial
olivocochlear efferent system functions, otoacoustic
emissions (OAEs) testing is one of the crucial clinical
and diagnostic tools, because it reveals the cochlear
component of hearing impairment. OAEs are generated
by active micromechanics of the outer hair cells (OHCs)
in the organ of Corti and they are low-intensity sounds
produced by the cochlea as a part of normal auditory
processes [10]. Distortion product otoacoustic emissions
(DPOAEs) precisely detect cochlear dysfunction as
frequency-specific and they are obtained in spite of hearing
loss to some degree, so they are preferred for assessment of
cochlear activity and medial olivocochlear efferent system
functions in the present research.
Moreover, the suppression of OAEs means a fair amount
of decrease in the response amplitude with contralateral
ear stimulation, which reduces the electromotility of the
OHCs and in particular suppresses OAEs. The suppression
is related to the efferent auditory pathway, which originates
from the superior olivary complex. Since the contralateral
sound-induced suppressive effect is mediated by the medial
superior olivary complex (MSOC) neurons, contralateral
suppression of OAEs gives direct information on MSOC
efferent activation. If the contralateral ear is stimulated
when noise is present, it can give an idea. This effect is
explained by the change of cochlear micromechanics
of the MSOC, which can be activated by contralateral
acoustic stimulation. The present study therefore explored
the suppression of emissions to investigate the medial
olivocochlear (MOC) system in pSS. Since the MOC
efferent system provides better hearing performance and
speech discrimination in noisy environments, disruption
of the MOC system, which can be evaluated by suppression
of OAEs, causes abnormalities of temporal functions
like discrimination, understanding, and lateralization of
sounds in a noisy environment [11].
However, there is little research on medial olivocochlear
efferent system function in pSS [8,12]. Therefore, this
study is the first to evaluate the functions of the MOC
efferent system related to neurosensory functions in pSS by
using contralateral suppression of DPOAEs. We expected
that MOC dysfunction in pSS patients adversely affects
neurosensory functions in the inner ear fluids and upper
auditory pathway. To reveal the importance of routine
audiological evaluations in pSS, the study also investigated
other audiological findings extensively.
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2. Materials and methods
All the subjects agreed to participate in this randomized
controlled study and provided signed informed consent
prior to the investigation. In addition to this, the study
was performed with institutional decision number 396
for ethical approval. Patients meeting the classification
criteria for pSS were evaluated for eligibility [13]. After
physical and laboratory examinations, disease activity was
measured with the EULAR Sjögren’s Syndrome Disease
Activity Index (ESSDAI) and patients with ESSDAI scores
of <14 were enrolled.
The exclusion criteria included high disease activity
(ESSDAI ≥14), exposure to noise, genetic hearing
loss, neurological disease, tinnitus, vertigo, ototoxic
medication, trauma, ear pathologies or ear surgery history,
and age over 75 years. A total of 36 pSS patients were
enrolled as the study group and 36 age- and sex-matched
healthy subjects with normal hearing thresholds were
enrolled as the control group. Since hydroxychloroquine
(HCQ) is frequently used in pSS and antimalarial drugs
are suspected to cause ototoxicity, hearing performance of
HCQ users and nonusers were also compared as subgroup
analysis in order to investigate possible ototoxic effects of
HCQ.
2.1. Pure tone-speech audiometry
All the audiological evaluations of the subjects were
performed by the same audiologist in a silent cabinet
with a GSI-AudioStar Pro clinical audiometer with air
conduction thresholds at frequencies of 125–8000 Hz and
bone conduction thresholds of 500–4000 Hz. The highfrequency hearing thresholds were found at frequencies
of 9000, 10,000, 11,200, and 12,500 Hz. Hearing loss was
classified as low frequency (125, 250, 500 Hz), middle
frequency (500, 1000, 2000 Hz), high frequency (4000,
6000, 8000 Hz), and very high frequency (9000, 10,000,
11,200, 12,500 Hz). Subjects with a limit of perception
below 20 dB HL at all frequencies were defined as normal
[14]. The pure tone threshold averages were calculated at
500, 1000, 2000, and 4000 Hz and hearing loss degrees were
defined according to established criteria [14]. The speech
audiometer was used to evaluate speech recognition
thresholds (SRT) and speech discrimination (SD) scores
and they were compared between the pSS and control
groups. Subjects who had speech discrimination scores
above 88% were defined as normal [14].
2.2. Acoustic immittance
Acoustic immittance involves the middle ear pressure,
the static compliances, and the presence of ipsilateral and
contralateral acoustic reflexes. A 226-Hz tympanometry
measurement and ipsilateral-contralateral acoustic reflexes
were assessed with the GSI TYPmpStar.
Subjects with middle ear pressures of 0–100 daPa
and compliance values of 0.33 mmHo to 1.33 mmHo
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were defined as normal. Acoustic reflexes of 75–95 dB
at frequencies of 500, 1000, 2000, and 4000 Hz were
considered normal [14].
2.3. Otoacoustic emissions
DPOAE measurement was performed with an Interacoustic
Eclipse 15 using insert earphones. The frequency ratio of
the two primary tones (f2/f1) was fixed at 1.22. Stimulus
levels were kept at 65 dB SPL for f1 and 55 dB SPL for
f2 frequencies. DPOAE measurement at 2f1 – f2 was
considered significantly different from the background
noise if it exceeded it by at least 3 dB. DPOAEs were
obtained between 1 kHz and 6 kHz, and signal-to-noise
ratios of these responses were compared between the pSS
and control groups. Additionally, white noise at 50 dB SPL
was used to stimulate the contralateral ear side during
otoacoustic emission measurement to evaluate MOC
activities [15–17].
2.4. Statistical analyses
SPSS 25 for Windows 7 was used for statistical analyses
(IBM Corp., Armonk, NY, USA) and P < 0.001 was
considered statistically significant. The variables were
investigated using visual (histogram and probability plots)
and analytical methods (Kolmogorov–Smirnov/Shapiro–
Wilk test) to determine whether or not they were normally
distributed. Descriptive analyses were presented using mean
and standard deviation for normally distributed variables,
while median and interquartile range (25th-75th IQR) were
used for abnormally distributed ones. The P-values result
from the independent samples t-test in the group that
demonstrated normal distribution and the Mann–Whitney
U-test was applied for nonparametric situations.
3. Results
3.1. Clinical findings
After consulting the inclusion and exclusion criteria,
we assessed 36 female subjects (72 ears) with pSS and
compared them with 36 healthy female subjects (72 ears).
The mean age of pSS patients and controls were 51.42 ±
10.21 years (range: 38–64 years) and 49.72 ± 4.19 years
(41–59 years) respectively. The subjects in the pSS group
were diagnosed about 20 months ago. The clinical profile
is summarized in Table 1. These findings are given in
the study only as descriptive statistics, so no correlation
between the clinical profile and auditory performance
of pSS patients was analyzed. Many of the subjects with
pSS complained about having communication problems
sometimes, including speech discrimination and
perception in noisy environments.
3.2. Audiological findings
The hearing thresholds were analyzed for right and left
ears in four groups of frequency ranges: 125–250–500 Hz
are low, 500–1000–2000 Hz are middle, 4000–6000–8000

Table 1. Clinical features of subjects with pSS (n = 36).
Age at inclusion, years§

51.42 ± 10.21

Duration, months

31.0 (5.0–36.0)

¶

Disease characteristics, n (%)
Arthralgia

35 (97.1)

Fatigue

34 (94.4)

Sicca symptoms

32 (88.9)

Arthritis

8 (22.2)

Systemic involvement

9 (25)

Anti-SSA positivity

20 (55.6)

Anti-SSB positivity

4 (8.3)

ANA positivity

31 (86.1)

RF positivity

5 (13.9)

Biopsy procedure

22 (61.1)

Positive biopsy

22 (100)

Hypocomplementemia

5 (13.9)

Hypergammaglobulinemia

4 (11.1)

ESR, mm/h

13.5 (1.0–65.0)

CRP, mg/L¶

4.0 (1.0–23.0)

¶

Data presented as mean ± SD; ¶ data presented as median (min–
max); ANA, antinuclear antibody; RF, rheumatoid factor; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein.
§

Hz are high, and 9000–10,000–11,200–12,500 Hz are very
high frequencies. The hearing threshold averages of pSS
patients were compared with the controls for all frequency
groups (Table 2).
In all the frequency ranges, a statistically significant (P
< 0.001) difference was found. Accordingly, the hearing
thresholds were obtained from both of the groups,
increasing gradually towards the very high frequency
range. The most significant difference was calculated
for the right ear in very high frequency range between
the pSS and control groups, because the thresholds were
observed at 45.62 dB in pSS patients while the controls had
a threshold at 22.15 dB (P < 0.001). Moreover, minimal to
mild sensorineural hearing loss was observed in 52.77%
of pSS patients (n = 19) according to pure tone averages.
According to a study on very high frequency hearing
thresholds in normal-hearing adults (9000–12,500 Hz), 30
subjects (83.33%) had high frequency hearing loss in the
current study [18].
The speech audiometry results showed a correlation
between pure tone averages and SRTs for the two groups.
In addition, SRTs were about 5–10 dB higher than pure
tone averages. The SD scores were determined with mean
and standard deviation of 94.11 ± 5.77% in pSS patients
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and similarly 96.22 ± 3.57% in the controls. Consequently,
the speech audiometry results were correlated with the
hearing thresholds for all subjects.
The tympanometry results of pSS patients and those of
the control group were analyzed by middle ear pressure and
static compliance values as shown in Table 3. All subjects
had type A curves; thus, the middle ear pressures and the
static compliances were in the normal range. However, one
point to be noted is that the static compliances of the pSS
group were lower than those of the control group, and when
these static compliances of pSS patients were compared
with the controls, a statistically significant difference (P
= 0.000) was found between the groups. Likewise, static
compliances for the right ears of pSS patients were about
0.49 mmHo, while they were 0.65 mmHo in the controls.
On the other hand, no statistically significant difference
was found in the middle ear pressures between the groups
(P = 0.299, P = 0.804).
The acoustic reflex thresholds of the pSS group were
higher than those of the control subjects as ipsilateral or
contralateral measurements and, related to this, statistically
significant differences were found at all frequencies (P =
0.000) (Table 4). Furthermore, in general, the obtained

contralateral acoustic reflex thresholds were higher than
the ipsilateral ones.
DPOAE responses were obtained from all the subjects,
but there was no significant difference (P > 0.001) (Table
5). Response amplitudes of 1 kHz and 2 kHz were found to
be higher than the other frequencies for both groups and
ear sides in general.
For suppression of DPOAEs, if the criterion of an
amplitude decrease of >1 dB was taken into account, a
suppressive effect was obvious in the pSS and control
groups [19]. The contralateral sound caused suppression
of the otoacoustic emission responses in subjects with
pSS; therefore, normal sensitivity to noise as the quality
of sound was perceived. The highest suppression levels
were observed at 1 kHz as 2.64 dB for pSS patients and as
2.60 dB for the controls (Table 6); however, there was no
statistically significant difference calculated between the
groups (P = 0.920). There was also no significant difference
at 1 kHz for suppression levels, nor was any significant
difference found at the other frequencies as shown by the
P-values.
A total of 13 pSS patients were HCQ nonusers for various
reasons (coexisting retinal disease, allergy, not preferred

Table 2. Pure tone audiometry results of subjects with pSS and controls
Frequency range

Ear side

pSS,
mean ± SD

Controls,
mean ± SD

P

Low-frequency average
(dB HL) (125, 250, 500 Hz)

Right

9.39 ± 6.29

4.39 ± 3.46

<0.001*

Left

10.41 ± 4.54

4.30 ± 3.71

<0.001*

Middle-frequency average
(dB HL) (500, 1000, 2000 Hz)

Right

14.30 ± 7.18

6.11 ± 4.17

<0.001*

Left

15.64 ± 5.72

5.41 ± 3.21

<0.001*

High-frequency average
(dB HL) (4000, 6000, 8000 Hz)

Right

21.52 ± 9.58

5.78 ± 3.49

<0.001*

Left

23.05 ± 8.90

6.48 ± 3.43

<0.001*

Very high-frequency average
(dB HL) (9000, 10,000, 11,200, 12,500 Hz)

Right

45.62 ± 17.60

22.15 ± 7.49

<0.001*

Left

44.20 ± 17.26

22.95 ± 9.03

<0.001*

*P < 0.05 (independent samples t-test).

Table 3. Tympanometry results of subjects with pSS and controls.

Middle ear pressure (daPa)
Static compliance (mmHo)

Ear side

pSS,
mean ± SD

Controls,
mean ± SD

P

Right

–8.94 ± 24.19

–3.80 ± 16.87

0.299

Left

–6.19 ± 23.77

–4.97 ± 17.24

0.804

Right

0.49 ± 0.16

0.65 ± 0.12

<0.001*

Left

0.51 ± 0.17

0.66 ± 0.13

<0.001*

*P < 0.05 (independent samples t-test).
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Table 4. Acoustic reflex thresholds of subjects with pSS and controls.
Acoustic reflexes thresholds

Ear side

pSS (dB),
mean ± SD

Controls (dB),
mean ± SD

P

Right

85.69 ± 3.99

81.94 ± 2.47

0.017*

Left

86.66 ± 4.78

84.44 ± 2.61

0.042*

Right

85.97 ± 3.54

81.80 ± 2.43

<0.001*

Left

86.80 ± 4.16

83.61 ± 2.56

<0.001*

Right

87.63 ± 3.27

83.05 ± 2.47

<0.001*

Left

88.19 ± 3.19

83.75 ± 3.01

<0.001*

Right

90.13 ± 2.23

85.13 ± 1.88

<0.001*

Left

90.69 ± 2.71

84.58 ± 3.01

<0.001*

Right

90.13 ± 3.87

85.27 ± 2.91

0.021*

Left

91.94 ± 4.18

86.94 ± 3.22

0.011*

Right

88.88 ± 2.42

83.88 ± 2.42

< 0.001*

Left

89.30 ± 3.41

84.44 ± 2.87

< 0.001*

Right

89.44 ± 2.87

84.16 ± 2.80

<0.001*

Left

89.58 ± 4.03

84.86 ± 3.48

<0.001*

Right

90.41 ± 3.24

84.58 ± 4.03

<0.001*

Left

91.66 ± 3.77

85.83 ± 3.48

<0.001*

Ipsilateral reflexes
500 Hz
1000 Hz
2000 Hz
4000 Hz
Contralateral reflexes
500 Hz
1000 Hz
2000 Hz
4000 Hz

*P < 0.05 (independent samples t-test).
Table 5. DPOAE amplitude of subjects with pSS and controls.

1 kHz, mean ± SD
2 kHz, mean ± SD
4 kHz, mean ± SD
6 kHz, median (IQR)

Ear side

pSS
(SNR dB)

Controls
(SNR dB)

P

Right

14.58 ± 4.09

13.20 ± 2.58

0.131

Left

13.86 ± 5.30

14.81 ± 2.66

0.362

Right

14.76 ± 3.40

11.73 ± 3.04

0.099

Left

13.21 ± 3.12

12.57 ± 2.59

0.344

Right

12.53 ± 2.92

9.39 ± 2.41

0.018*

Left

11.07 ± 3.43

9.72 ± 2.12

0.032*

Right

7.25 (5.40–7.90)

3.70 (3.10–4.10)

0.068

Left

5.95 (5.20–7.50)

4.50 (4.10–5.80)

0.016**

*P < 0.05 (independent samples t-test), **P < 0.05 (Mann–Whitney U-test).

by physician, etc.). Subgroup analyses revealed no
significant difference in hearing performance between
HCQ users and nonusers (mean hearing thresholds,
P = 0.612; mean middle ear pressure, P = 0.869; mean
acoustic reflexes thresholds, P = 0.315; mean DPOAE
amplitude, P = 0,281; mean DPOAE suppression level, P
= 0.685; independent samples t-test). When compared

to healthy subjects, HCQ nonusers had impairment
similar to the general pSS population in the study
(mean hearing thresholds, P = 0.03; mean middle ear
pressure, P = 0.128; mean acoustic reflexes thresholds,
P = 0.018; mean DPOAE amplitude, P = 0,035; mean
DPOAE suppression level, P = 0.452; independent
samples t-test).
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Table 6. DPOAE suppression level of subjects with pSS and controls.

1 kHz, mean ± SD
2 kHz, mean ± SD
4 kHz, mean ± SD
6 kHz, median (IQR)

Ear side

pSS
(dB)

Controls
(dB)

P

Right

2.64 ± 2.12

2.60 ± 1.84

0.920

Left

2.08 ± 2.42

2.88 ± 2.05

0.134

Right

1.96 ± 1.90

1.97 ± 2.04

0.980

Left

2.08 ± 2.00

1.98 ± 1.91

0.817

Right

2.06 ± 2.01

2.06 ± 2.21

0.955

Left

2.28 ± 1.58

1.40 ± 2.23

0.191

Right

0.75 (0.00 to 1.70)

1.00 (0.60 to 2.30)

0.684

Left

0.55 (–0.70 to 1.50)

1.70 (1.40 to 2.40)

0.122

*P < 0.05 (independent samples t-test), **P < 0.05 (Mann–Whitney U-test).

4. Discussion
This study is the first to reveal the functions of the MOC
efferent system related to auditory neurosensory functions
in pSS and also examine the audiological findings
extensively in pSS.
We found minimal to mild sensorineural hearing loss
in more than half of our pSS subjects, possibly resulting
from degeneration of inner ear fluids with pSS. Because
the cochlea is a sensory organ that transforms auditory
inputs to neurosensory functions, this mechanism is
tightly dependent on the fluids in the inner ear, which
contain several proteins and other molecules. Similarly,
the molecules of the inner ear fluids degenerate from
secondary Sjögren’s syndrome or Meniere’s disease and
thus hearing loss can be observed in subjects with pSS
[5]. Accordingly, this study implies that subjects with pSS
are more likely to suffer hearing loss than their controls
compatible, with the literature.
The main aim of this study was not to evaluate highfrequency hearing loss and the present study included
a small number of subjects with pSS according to some
other studies in the literature for investigating only highfrequency hearing loss. However, we also examined these
findings because of some communication problems
among our subjects with pSS. Consequently, most of the
subjects with pSS had hearing loss in both ears at very high
frequencies (9000–12,500 Hz), which is in accordance
with other studies [8,9]. A significant difference at 125–
250–500 Hz between the groups was obtained, differently
from some other studies [6]. The statistically significant
differences between the pSS and control groups were
detected not only at very high frequencies but also in all
other frequency ranges (low, middle, high), unlike other
studies [7]. The auditory damage resulting from pSS was
particularly seen at very high frequencies in the current
study, which is supported by some other studies about
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high-frequency audiometry thresholds of pSS [6,8]. These
findings may be based on indefinite pathophysiological
impacts that pSS may have on the auditory system, such
as effects of dryness on neurosensory elements in the
inner ear. High-frequency hearing loss can be difficult
to recognize in daily life, so many subjects with pSS are
unaware of it. For this reason, high-frequency audiometry
should be carried out routinely. It is very important for
early detection of hearing loss of not only patients with
pSS but also those with other autoimmune diseases.
The present study also investigated middle ear
pressures, static compliances, and statistical analyses
of these values between the groups. Little research has
examined tympanometry results comprehensively [7,8].
Only evidence about the type of tympanogram was
presented in these studies. Not only was a type A curve
obtained from all of the subjects in current study, but
also the static compliances of the pSS group were lower
than those of the controls. Many studies presented their
results in most rheumatoid arthritis subjects as only type
A tympanometry curves [8], but the tympanic membrane
structure, motility, or middle ear fluids and muscle
mechanisms can suffer in cases of pSS. Similarly, some
studies reported that conductive hearing loss was observed
in some subjects and they supposed that it could be due to
dryness of the mucous membranes of the Eustachian tube
and middle ear fluids [20].
Acoustic reflex thresholds were obtained in the normal
range for both groups; therefore, retrocochlear pathology
was not considered for the subjects with pSS. The acoustic
reflex thresholds at high frequency are higher than the
low ones, which was expected as that is consistent with
increased high-frequency hearing thresholds in the pSS
group.
The results of DPOAEs in all frequency ranges were
observed in the pSS group, but one point to be noted is that
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response amplitudes of the pSS group were 6 kHz. This is
consistent with decreased hearing thresholds towards high
frequencies in pSS. There was no statistically significant
difference for amplitudes between the pSS and control
groups, so OHC functions and cochlear nonlinearity
mechanisms can be considered normal in the pSS group.
This may be explained by minimal or mild hearing loss in
the pSS group, because of the hearing loss degrees, and so
the functions may not suffer. About half of our subjects
had minimal to mild hearing loss and these otoacoustic
emission amplitudes can possibly decrease gradually to high
frequencies because of the hearing loss progressing towards
very high frequencies, like in some other studies [21].
Finally, it may be the most important point of this study
that we investigated the auditory efferent neural pathway of
pSS patients since there is a huge need for such evaluations
in autoimmune diseases. Because only DPOAEs indicate
that there are no direct implications for normal functions
of the MOC efferent system, the present study explored
the suppression of emissions to investigate the medial
olivocochlear system in pSS should an abnormality of
this system be suspected. Disorders of the MOC efferent
system, which can be evaluated by suppression of OAEs,
cause abnormalities of some auditory neural functions.
Nevertheless, in this study, the demonstration of the normal
functioning of the MOC reflex in subjects with pSS may
indicate that the olivocochlear efferent system is functional.

Some other physiological changes such as atrophy of
the spiral ganglion cells due to pSS cause sensorineural
hearing loss; therefore, subjects with pSS may have
neurological symptoms. The several autoantibodies that
regulate the immune system suffer from autoimmune
diseases; therefore, multiple problems like polyneuropathy
may be revealed [22,23].
Ototoxicity is reported as a rare side effect of
antimalarial drugs [24]. To clarify whether HCQ exposure
interfered with the study results we performed subgroup
analyses. Based on our subgroup analyses, exposure to
HCQ did not seem to significantly affect the auditory test
results of pSS patients in this study.
In conclusion, these findings suggest that there is no
synchronization problem in the efferent system, but the
knowledge about the central afferent auditory system
can be assumed only by acoustic reflexes in the present
study. On the other hand, there is a need for more
audiological evaluations, including wide-scale auditory
brainstem response assessment, to see whether there is a
synchronization problem in the afferent auditory system in
subjects with pSS. Consequently, medical experts should
refer subjects with pSS for extensive hearing assessments
periodically for detecting possible audiological damage.
Further studies should comprehensively investigate the
auditory neural pathways not only in pSS but also in all
other autoimmune diseases.
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